Skip to main content
    S

    Sight Sciences Inc (SGHT)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $10.59
    -0.24 (-2.22%)

    Market Cap: $601.92M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Sight Sciences Inc (SGHT) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Sight Sciences (SGHT) is expected to report earnings on Mar 2, 2027. In the quarter ended Sep 30, 2026, Sight Sciences reported EPS of -$0.12, in line with the -$0.12 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    48%(11/23)
    Avg Surprise
    -6.74%

    Upcoming Estimates

    Reports Mar 2, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.14
    Range-$0.17 - -$0.08
    9 analysts
    Revenue Consensus
    $25.15M
    Range$23.27M - $27.20M
    10 analysts
    Reports May 4, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.12
    Range-$0.16 - -$0.07
    4 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.06-81.0%
    60d ago-$0.06-81.0%
    30d ago-$0.06-81.0%
    7d ago-$0.07-80.8%
    Current-$0.12
    Revenue Consensus
    $22.88M
    Range$22.50M - $23.13M
    5 analysts

    Next Report

    SGHT has an expected report date of Mar 2, 2027.

    SGHT Earnings Call

    The latest SGHT earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 23 quarters below that had an estimate, SGHT beat 11, missed 10 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $24.92M, up 25.2% from $19.91M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.12-$0.12-$0.15 - -$0.080.00%In lineN/A6N/ANov 4, 2026$24.92M
    Jun 30, 2026-$0.08-$0.15-$0.18 - -$0.07+46.67%BeatN/A51 up, 0 downAug 5, 2026$23.39M
    Mar 31, 2026-$0.24-$0.20-$0.21 - -$0.19-20.00%MissN/A33 up, 0 downMay 6, 2026$19.70M
    Dec 31, 2025-$0.08-$0.15-$0.24 - -$0.09+47.68%BeatN/A51 up, 0 downMar 4, 2026$20.39M
    Sep 30, 2025-$0.16-$0.26-$0.34 - -$0.13+38.46%BeatN/A53 up, 1 downNov 6, 2025$19.91M
    Jun 30, 2025-$0.23-$0.25-$0.32 - -$0.21+8.00%BeatN/A63 up, 0 downAug 7, 2025$19.56M
    Mar 31, 2025-$0.28-$0.23-$0.30 - -$0.19-21.74%MissN/A30 up, 3 downMay 8, 2025$17.51M
    Dec 31, 2024-$0.23-$0.18-$0.24 - -$0.11-30.68%MissN/A42 up, 0 downMar 5, 2025$19.07M
    Sep 30, 2024-$0.22-$0.21-$0.31 - -$0.11-4.76%MissN/A70 up, 0 downNov 7, 2024$20.16M
    Jun 30, 2024-$0.25-$0.30-$0.32 - -$0.25+16.67%BeatN/A60 up, 0 downAug 1, 2024$21.37M
    Mar 31, 2024-$0.29-$0.28-$0.35 - -$0.21-3.57%MissN/A60 up, 0 downMay 2, 2024$19.27M
    Dec 31, 2023-$0.22-$0.32-$0.44 - -$0.20+31.25%BeatN/A50 up, 0 downMar 7, 2024$18.75M
    Sep 30, 2023-$0.27-$0.33-$0.40 - -$0.22+18.18%BeatN/A60 up, 0 downNov 7, 2023$20.01M
    Jun 30, 2023-$0.30-$0.34-$0.42 - -$0.27+11.76%BeatN/A70 up, 0 downAug 3, 2023$23.47M
    Mar 31, 2023-$0.35-$0.39-$0.45 - -$0.31+10.26%BeatN/A70 up, 0 downMay 4, 2023$18.82M
    Dec 31, 2022-$0.35-$0.42-$0.48 - -$0.38+16.67%BeatN/A70 up, 0 downMar 13, 2023$20.54M
    Sep 30, 2022-$0.46-$0.46-$0.49 - -$0.430.00%In lineN/A70 up, 0 downNov 10, 2022$18.68M
    Jun 30, 2022-$0.50-$0.42-$0.49 - -$0.30-19.05%MissN/A50 up, 0 downAug 11, 2022$17.23M
    Mar 31, 2022-$0.49-$0.40-$0.46 - -$0.35-22.50%MissN/A41 up, 0 downMay 10, 2022$14.88M
    Dec 31, 2021-$0.34-$0.39-$0.44 - -$0.37+12.82%BeatN/A40 up, 0 downMar 24, 2022$14.69M
    Sep 30, 2021-$0.43-$0.37-$0.41 - -$0.34-16.22%MissN/A32 up, 0 downNov 10, 2021$13.10M
    Jun 30, 2021-$1.83-$1.72-$1.83 - -$0.33-6.40%MissN/A2N/AJul 15, 2021$12.54M
    Mar 31, 2021-$1.29-$0.35N/A-268.57%MissN/AN/AN/AJun 2, 2021$8.63M
    Dec 31, 2020-$2.57N/AN/AN/AN/AN/AN/AN/AMar 31, 2021$8.99M
    Dec 31, 2019-$1.94N/AN/AN/AN/AN/AN/AN/AMar 31, 2020N/A
    Last 25 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.75, after -$0.99 the year before. It was -$1.94 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.75N/A
    Dec 31, 2024-$0.99N/A
    Dec 31, 2023-$1.14N/A
    Dec 31, 2022-$1.80N/A
    Dec 31, 2021-$3.89N/A
    Dec 31, 2020-$2.57N/A
    Dec 31, 2019-$1.94N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,900 words across 12 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20266,93112
    2026Q2Jun 30, 20265,42611
    2026Q1Mar 31, 20265,76111
    2025Q4Dec 31, 20255,33711
    2025Q3Sep 30, 20256,29511
    2025Q2Jun 30, 20255,47110
    2025Q1Mar 31, 20257,08411
    2024Q4Dec 31, 20248,92311

    2026Q3 Earnings Call

    Opening remarks

    Hannah Jeffrey Investor Relations Thank you for participating in today's call. Presenting today are Sight Sciences Co-Founder and Chief Executive Officer, Paul Badawi, and Chief Financial Officer, Jim Rodberg. Also in attendance is Sight Sciences' Chief Operating Officer, Ali Bauerlein. Earlier today, Sight Sciences released financial results for the third quarter ended September 30, 2026, raised its revenue guidance and maintained its adjusted operating expense guidance for the full year 2026. A copy of the press release is available on our website at investors.sightsciences.com. I would like to remind everyone that comments made by management today and answers to questions will include forward-looking statements within the meaning of federal securities laws. These statements are based on plans and expectations as of today, which may change over time. In addition, actual results could differ materially from projected results due to a number of risks and uncertainties. For a discussion of risks and other factors that may affect the company's future financial results and business, please refer to the earnings release issued prior to this call and the company's SEC filings. We undertake no obligation to publicly update or revise any forward-looking statements, except as required by law. Also on this call, management refers to certain financial measures that are not prepared in accordance with generally accepted accounting principles in the United States, including adjusted operating expenses. We believe these non-GAAP financial measures are important indicators of the company's operating performance because they exclude items that are unrelated to and may not be indicative of its core operating results. See our earnings release for a reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures, as well as additional information about our reliance on non-GAAP financial measures. I'll now turn the call over to Paul.

    Paul Badawi Co-Founder and CEO Thanks, Hannah. Good afternoon, and thank you for joining us. We are extremely proud of our results again this quarter, where we reported record revenue of $24.9 million, growing 25% year-over-year. This marks our third consecutive quarter of double-digit growth and second consecutive quarter of 20% growth or greater. IDE revenue continues to scale rapidly and reached another record quarter with revenue of $3.9 million, and IG continued its momentum and grew 7% to $21 million. Notably, we delivered this high-growth performance while both investing in our growth drivers and significantly improving our cash burn, highlighting the operating leverage in our commercial model. Based on our strong results and outlook, we are raising our full-year 2026 revenue guidance while maintaining our adjusted operating expense guidance. At Sight Sciences, we are focused on delivering minimally invasive technologies that address the underlying cause of two of the most common anterior segment diseases, glaucoma and dry eye disease.

    Frequently Asked Questions About SGHT

    When is Sight Sciences's next earnings date?

    Sight Sciences's next earnings report is expected for Mar 2, 2027.

    Did SGHT beat earnings estimates last quarter?

    Sight Sciences reported EPS of -$0.12 for the quarter ended Sep 30, 2026, in line with the -$0.12 estimate.

    What EPS do analysts expect from SGHT next quarter?

    The consensus EPS estimate for Sight Sciences for the quarter ending Dec 31, 2026 is -$0.14 from 9 analysts, with estimates from -$0.17 to -$0.08.

    How often does SGHT beat earnings estimates?

    Sight Sciences beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +8.55%.